Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: Observations on regression and cancer incidence

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 6, 2006, Pages 727-733

  Cooper, B T ^a   Chapman, W ^a   Neumann, C S ^a   Gearty, J C ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER RISK; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG DOSE REGIMEN; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; INTESTINE METAPLASIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; ESOPHAGEAL DISEASES; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMPS; SEX FACTORS; TREATMENT OUTCOME;

EID: 33644781586     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02825.x     Document Type: Article

References (59)

1. Iascone C DeMeester TR Little AG Skinner DB Barrett's esophagus; functional assessment, proposed pathogenesis and surgical therapy Arch Surg 1983 118 543 9
2. Cooper BT Barbezat GO Barrett's oesophagus. A clinical study of 52 cases Q J Med 1987 62 97 108
3. Tytgat GNJ Hammeetman W Onstenk RR Scotberg R The spectrum of columnar lined (Barrett's) oesophagus Endoscopy 1989 21 177 85
4. Paull A Trier JS Dalton MD Camp RC Loeb P Goyal RK The histological spectrum of Barrett's esophagus N Engl J Med 1976 295 476 80
5. Rothery GA Patterson JE Stoddard CJ Day DW Histological and histochemical changes in the columnar lined (Barrett's) oesophagus Gut 1986 27 1062 8
6. Skinner DB Walther BC Riddell RH Schmid H Iascone C DeMeester TR Barrett's esophagus. Comparison of benign and malignant cases Ann Surg 1983 198 554 65
7. Spechler SJ Robbins AH Rubin HB et al. Adenocarcinoma and Barrett's esophagus. An overrated risk Gastroenterology 1984 87 927 35
8. Kerlin P Mellow GD van Deth A Barrett's oesophagus. Clinical endoscopic and histologic spectrum in 50 cases Aust N Z J Med 1986 16 198 205
9. Reid BJ Haggitt RG Rubin CE Rabinovitch PS Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk of adenocarcinoma Gastroenterology 1987 93 1 11
10. Brand DL Ylvisakar JF Gelfand M Pope CE Regression of the columnar esophageal (Barrett's) epithelium after anti-reflux surgery N Engl J Med 1980 302 844 8
11. Skinner DB Walther BC Riddell RH Schmidt H Iascone C DeMeester TR Barrett's esophagus Ann Surg 1983 198 554 65
12. Starnes BA Adkins RB Ballinger JF Barrett's esophagus: a surgical entity Arch Surg 1984 119 563 7
13. Williamson WA Ellis FH Gibb SP Shahian DM Aretz HT Effects of anti-reflux operation on Barrett's mucosa Ann Ther Surg 1990 49 537 42
14. Barham CP Jones RL Biddlestone IR et al. Photothermal laser ablation of Barrett's oesophagus: endoscopic and histological evidence of squamous re-epithelialisation Gut 1997 41 281 4
15. Basu KK Pick B Bale R et al. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium Gut 2002 51 776 80
16. Sampliner RE Faigel D Fennerty MB et al. Effectiveness and safe endoscopic reversal of non dysplastic Barrett's esophagus with thermal electrocoagulation combined with high dose acid inhibition Gastrointest Endosc 2001 53 554 8
17. Overholt BF Panjehpour M Haydek JM Photodynamic therapy for Barrett's esophagus: follow up of 100 patients Gastrointest Endosc 1999 49 1 7
18. Deviere J Barrett's oesophagus: the new endoscopic modalities have a future Gut 2005 54 i33 8
19. Berensen MM Johnson TD Markowitz NR Samowitz WS Restoration of squamous epithelium after ablation of Barrett's esophagus Gastroenterology 1993 104 1686 91
20. Cooper BT Barbezat GO Treatment of Barrett's with H2 blockers J Clin Gastroenterol 1987 9 139 41
21. Neumann CS Iqbal TH Cooper BT Long term continuous omeprazole treatment of patients with Barrett's oesophagus Aliment Pharmacol Ther 1995 9 451 4
22. Peters FTM Ganesh S Kuipers EJ et al. Endoscopic regression of Barrett's oesophagus during omeprazole therapy Gut 1999 45 489 94
23. Klinkenberg-Knoll EC Festen HP Jansen JB et al. Long term treatment with omeprazole for erosive esophagitis Ann Intern Med 1994 121 161 7
24. Sharma P Sampliner RE Camargo E Normalisation of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus Am J Gastroenterol 1997 92 582 5
25. Weinstein WF Lieberman DA Landis KJ Weber LJ Berger ML Ippoliti AF Omeprazole induced regression of Barrett's esophagus: a two year randomized controlled double blind trial Gastroenterology 1996 110 A294
26. Cooper BT Neumann CS Cox MA Iqbal TH Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus Aliment Pharmacol Ther 1998 12 893 7
27. Malesci A Savarino V Zentilin P et al. Partial regression of Barrett's esophagus by long term therapy with high dose omeprazole Gastrointest Endosc 1996 44 700 5
28. Wilkinson SP Biddlestone L Gore S Shepherd NA Regression of columnar lined Barrett's oesophagus with omeprazole 40 mg daily: results of five years continuous therapy Aliment Pharmacol Ther 1999 13 1205 9
29. Weston AP Badr AS Hassanein RS Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus Am J Gastroenterol 1999 94 3420 6
30. Srinivasan R Katz PO Ramakrishnan A Katzka DA Vela MF Castell DO Maximal acid reflux control: feasible and effective Aliment Pharmacol Ther 2001 15 519 24
31. Howden CW Horning CA Do proton pump inhibitors induce regression in Barrett's esophagus Gastroenterology 1997 112 A152
32. Jankowski JA Provenzale D Moayyeddi P Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west Gastroenterology 2002 122 588 91
33. Sampliner RE Steinbronn K Garewal HS Riddell RH Squamous mucosa overlying columnar epithelium in Barrett's esophagus in the absence of anti-reflux surgery Am J Gastroenterol 1988 83 510 2
34. Drewitz DJ Sampliner RE Garewal HS The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years Am J Gastroenterol 1997 92 212 5
35. Shaheen NJ Crosby MA Bozymski EM Sandler RS Is there publication bias in the reporting of cancer risk in Barrett's esophagus Gastroenterology 2000 119 333 8
36. Jankowski JA Anderson M Review article: Management of oesophageal adenocarcinoma - control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus Aliment Pharmacol Ther 2004 20 Suppl. 5 71 80
37. Gladman L Chapman W Iqbal TH Cooper BT Barrett's oesophagus: an audit of surveillance over 15 years Gut 2004 53 A54
38. Basu KK de Caestecker JS Audit of a Barrett's epithelium surveillance database Eur J Gastroenterol Hepatol 2004 16 171 5
39. Murray L Watson P Johnston B Sloan J Mainie IML Risk of adenocarcinoma in Barrett's oesophagus: a population based study BMJ 2003 327 534 5
40. Solaymani-Dodaran M Logan RFA West J Card T Coupland C Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux Gut 2004 53 1070 4
41. Hammeetman W Tytgat GNJ Houthoff HJ van den Tweel JG Barrett's esophagus: development of dysplasia and adenocarcinoma Gastroenterology 1989 96 1249 56
42. Reid BJ Blount PL Rubin CE Levine DS Haggitt RC Rabinovitch PS Flow cytometry and histological progression to malignancy in Barrett's esophagus Gastroenterology 1992 102 1212 9
43. Vieth M Stolte M Barrett's esophagus and neoplasia Gastroenterology 2002 122 590
44. Fitzgerald RC Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation Gut 2005 54 i21 6
45. Fitzgerald RC Omary MB Triadafilopoulos G Dynamic effects of acid on Barrett's esophagus: an ex vivo differentiation and proliferation model J Clin Invest 1996 68 2120 8
46. Souza RF Shewmake K Terada LS et al. Acid exposure activates mitogen activated protein kinase pathways in Barrett's esophagus Gastroenterology 2002 122 299 307
47. Wilson KT Fu S Ramanujam KS et al. Increased expression of inducible nitric oxide synthase and cyclo-oxygenase 2 in Barrett's esophagus and associated adenocarcinoma Cancer Res 1998 58 2929 34
48. Shirvani V Ouatu-Luscar R Kaur B et al. Cyclo-oxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure Gastroenterology 2000 118 467 96
49. Ouatu-Luscar R Fitzgerald RC Triadafilopoulos G Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression Gastroenterology 1999 117 327 5
50. Umansky M Yasui W Hallak A et al. Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus Oncogene 2001 20 7987 91
51. Kaur BS Khamnehei N Iravani M et al. Rofecoxib inhibits cyclo-oxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus Gastroenterology 2002 123 60 7
52. Spechler S Lee E Ahnen D et al. Long term outcome of medical and surgical treatments for gastro-esophageal disease: follow up of a randomised trial J Am Med Assoc 2001 285 2331 8
53. Ye W Chow WH Lagergren J et al. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastro-esophageal diseases and after anti-reflux surgery Gastroenterology 2001 121 1286 93
54. Luostarinen M Isolauri J Laitinen J et al. Fate of Nissen fundoplication after 20 years. A clinical, endoscopical and functional analysis Gut 1993 34 1015 20
55. Hillman LC Chiragakis L Shadbolt B Kaye GL Clarke AC Proton pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus Med J Aust 2004 180 387 91
56. Farrow DC Vaughan TL Hansten PD et al. Use of aspirin and other non-steroidal anti-inflammatory drugs and the risk esophageal and gastric cancer Cancer Epidemiol Biomarkers Prev 1998 7 97 102
57. Basetti C Talamini R Franceschi SS et al. Asprin use and cancers of the upper aerodigestive tract Br J Cancer 2003 88 672 4
58. Castell DO Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in patients with Barrett's esophagus Am J Gastroenterol 1994 89 989 91
59. Ouatu-Lascar R Triadafilopoulos G Complete elimination of reflux symptoms does not guarantee normalisation of intra-esophageal acid reflux in patients Barrett's esophagus Am J Gastroenterol 1998 93 711 6